Irritable Bowel SyndromeNCT06413004
Brachyspira and Intestinal Allergy-like Immune Reactions in Patients With Irritable Bowel Syndrome (IBS)
A study testing Elimination and re-introduction of CLE or COLAP positive food item(s) in people with Irritable Bowel Syndrome and Food Sensitivity, run by Magnus Simrén at 1 site in Sweden.
Trial summary
The aim of this study is to define local immune responses in the GI tract to food antigens in IBS patients, with and without Brachyspira infection, using advanced imaging. We hypothesize that Brachyspira infection can cause IBS symptoms by inducing loss of oral tolerance to dietary antigens through development of… Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Irritable Bowel Syndrome, Food Sensitivity
- What is being tested?
- Elimination and re-introduction of CLE or COLAP positive food item(s)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 1 siteSweden
- Study dates
- 3 Aug 2022to 1 Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with IBS diagnosis according to their treating physician (ROME IV).
- Association between intake of food and GI symptoms.
- Witnessed written informed consent prior to any study procedures.
- Patients who are capable to understand the study and the questionnaires, and to comply with the study requirements.
Who cannot join
- Patients with relevant concurrent organic GI disease (inflammatory bowel disease, abdominal cancer), or a major disease such as diabetes, uncontrolled thyroid disease, heart disease, kidney disease, liver disease, and active malignant disease (not those that were in remission at least 5 years).
- Patients with a history of bowel surgery (not appendectomy or cholecystectomy) that affects GI motility.
- Patients with systemic food allergy as evidenced by positive allergy tests (blood, prick test).
- Clinical history of severe allergic reactions.
- Patients with concurrent major confounding condition(s) based on the clinician's judgement, e.g. DOMINANT psychiatric disorder, vital depression, alcohol or substance abuse in the last 2 year.
- Female patients who are pregnant or lactating (females of fertile age are requested to use a safe contraceptive) at the time of inclusion.
- Patients who use or used new medications that affect the GI functioning within 1 month before the start of the study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Sweden1 site, 1 recruiting
- Recruiting
Mag-tarmlab, Dept of Internal Medicine, Sahlgrenska University Hospital
Gothenburg, 413 45
MagTarmlab ., ., +46 31 342 81 07, magtarmlab.se@vgregion.se
00460313428107
About this study
The aim of this study is to define local immune responses in the GI tract to food antigens in IBS patients, with and without Brachyspira infection, using advanced imaging. We hypothesize that Brachyspira infection can cause IBS symptoms by inducing loss of oral tolerance to dietary antigens through development of food-specific intestinal immune reactions and subsequent development of visceral hypersensitivity.
During this study, the investigators will perform confocal laser endomiscroscopy (CLE) and/or colonoscopic antigen provocation test (COLAP) to test to which food items the participants react to. Furthermore, the investigators will perform rectal barostat examination and a sigmoidoscopy without laxatives. The investigators will collect biological samples and the participants will complete several questionnaires.
Read the detailed description
The aim of this study is to define local immune responses in the GI tract to food antigens in IBS patients with and without Brachyspira infection using advanced imaging. The investigators hypothesize that Brachyspira infection can cause IBS symptoms by inducing loss of oral tolerance to dietary antigens through development of food-specific intestinal immune reactions and subsequent development of visceral hypersensitivity.
Visit 1: inclusion, questionnaires, blood, rectal barostat examination Visit 2: questionnaires, blood, stool, diaries (food and stool), sigmoidoscopy (without laxantives) Allergologist visit (skin prick test and interpretation blood results) Visit 3A: stool, confocal laser endomicroscopy (CLE) OR colonoscopic antigen provocation test (COLAP) Visit 3B: facultative: in a subset of individuals, both CLE and COLAP will be performed (during separate visits)
Visit 4,5 and 6 only if the CLE or COLAP was positive for (at least) 1 food item
Visit 4: questionnaires and dietician-led instruction which food item to exclude (positive food item(s) during CLE/COLAP,), exclusion for 4 weeks. If both CLE and COLAP are positive, the diet will be COLAP-based.
Visit 5: questionnaires, stool diary, instructions re-introduction food item(s) Visit 6: questionnaires
QUESTIONNAIRES Baseline questionnaires; demographic, symptoms, symptom/medication/diet history, co-morbid medical conditions
IBS symptoms: IBS-Symptom Severity Scale (IBS-SSS) and Gastrointestinal Symptom Rating Scale (GSRS)-IBS
Psychological distress: Hospital Anxiety and Depression Scale (HADS), Patient Health Questionnaire (PHQ)-9 (both visit 1,4,5,6, generalized Anxiety Disorder 7-item scale (GAD-7)
Somatization: PHQ-15 for the number and severity of bodily symptoms.
Gastrointestinal specific anxiety: Visceral Sensitivity Index (VSI).
Sensitivity: Central Sensitization Inventory (CSI).
Food avoidance and restriction: (ARFID).
Stool habits and GI symptoms: 14-day GI symptom diary based on Bristol Stool Form Scale (BSFS).
Quality of life: IBS-Quality of Life (QOL).
Food intake: 4-days food diary, MealQ.
COLONOSCOPIC ALLERGEN PROVOCATION TEST, COLAP:
- A local allergen provocation test, where dietary antigens (soy, wheat, (egg), gluten and milk), with saline and histamine as negative and positive controls, respectively are injected in the rectosigmoid mucosa (similar to skin prick test used for clinical allergy testing).
- The intestinal reaction is determined visually ("wheal and flare reaction"), and biopsies are taken to characterize the immune response.
- Bowel preparation before the investigation follows the normal clinical routine for colonoscopy, and i.v. sedatives and opioids are given during the investigation according to clinical routines at the endoscopy unit
CONFOCAL LASER ENDOMICROSCOPY, CLE, gastroscopy:
- A probe-based endoscopic technique to study intestinal food reactions after iv injection of fluorescein.
- Disruption of the small intestinal barrier in duodenum upon exposure to food antigens (soy, wheat, egg, gluten, milk, and control) can be determined.
VISCERAL SENSITIVITY:
•Rectal barostat sensitivity measurement: With the rectal barostat, the investigators can measure the rectal sensitivity. A balloon is inserted and inflated in the rectum in a controlled setting. The patient indicates when defined sensory thresholds are reached (first feeling of the balloon, urge to empty bowel, discomfort or pain). When the patient indicates discomfort or pain, or another reason to stop, the balloon inflation will be stopped.
SIGMOIDOSCOPY:
•Flexible sigmoidoscopy without bowel preparation, to interfere as little as possible with the normal gut microenvironment; fresh biopsies for specific analyses and biopsies stored for subsequent analyses.
BIOLOGICAL SAMPLES:
- Blood - and plasma samples: Fasting blood samples are taken for routine blood tests (exclusion of organic diseases) and to determine the metabolic profile and genetic and immunological markers of relevance to intestinal function and nerve function. Serum samples will be analyzed with nuclear magnetic resonance (NMR) for metabolomic profile and microbial composition.
- Fecal - and urine sample: The investigators will characterize the composition and function of the metabolome in detail via 16S analysis, metagenomics, transcriptomics, metabolomics, cell culture and cell count. Urine and fecal samples will also be analyzed with nuclear magnetic resonance (NMR) for metabolomic profile and microbial composition.
- Biopsies (location based on the performed endoscopic examination): The investigators will conduct a detailed analysis of immune cells, proteins, nerve cells, and intestinal bacteria which will allow detailed mapping of intestinal function with respect to nerve, immune and barrier function.
- Conditions
- Irritable Bowel Syndrome, Food Sensitivity
- Being tested
- Elimination and re-introduction of CLE or COLAP positive food item(s)
- Keywords
- Irritable Bowel Syndrome, Food Sensitivity, Confocal Laser Endomicroscopy, Colonoscopic Antigen Provocation Test
- Medical subject headings
- Irritable Bowel Syndrome, Food Intolerance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Elimination and re-introduction of CLE or COLAP positive food item(s)Other
Elimination (4 weeks) and re-introduction (4 weeks) of all CLE or COLAP positive food item(s)
| Study group | Role | What they receive |
|---|---|---|
| Positive food item during CLE or COLAP | Other | The food item(s) which were positive during CLE (fluorescein leakage and cell shedding) or COLAP (swelling). Receives: Other: Elimination and re-introduction of CLE or COLAP positive food item(s) |
What is being measured
The primary outcome is the main question the study is designed to answer.
IBS-SSS (Irritable Bowel Syndrom Severity Scoring System) after exclusion (proportion).
the proportion of participants with an IBS-SSS reduction of ≥50 points, measured before (visit 4) and after (visit 5) exclusion of the CLE or COLAP positive food item(s) (= responders). IBS-SSS: higher IBS-SSS indicate more severe symptoms. Scores ranging 0-500.
Measured: 4 weeks after exclusion
Secondary outcomes (9)
IBS-SSS (Irritable Bowel Syndrom Severity Scoring System) after exclusion (absolute)
IBS-SSS: absolute change of IBS-SSS, measured before (visit 4) and after (visit 5) EXCLUSION of the CLE or COLAP positive food item(s). Higher IBS-SSS indicate more severe symptoms. Scores ranging 0-500.
Measured: 4 weeks after exclusion
IBS-SSS (Irritable Bowel Syndrom Severity Scoring System) after reintroduction (proportion)
IBS-SSS: the proportion of participants with an IBS-SSS increase of ≥50 points, measured before (visit 5) and after (visit 6) the REINTRODUCTION of the CLE or COLAP positive food item(s): responders vs non-responders (as based on the primary outcome). Higher IBS-SSS indicate more severe symptoms. Scores ranging 0-500.
Measured: 4 weeks after reintroduction
IBS-SSS (Irritable Bowel Syndrom Severity Scoring System) after reintroduction (absolute)
IBS-SSS: the absolute change of IBS-SSS, measured before (visit 5) and after (visit 6) the REINTRODUCTION of the CLE or COLAP positive food item(s): total group and responders vs non-responders (as based on the primary outcome)
Measured: 4 weeks after reintroduction
GSRS-IBS (the Gastrointestinal Symptom Rating Scale Irritable Bowel Syndrome version) after exclusion
change of total and subscores before (visit 4) and after (visit 5) EXCLUSION of the CLE or COLAP positive food item(s). Total group and responders vs non-responders (as based on the primary outcome). Higher GSRS-IBS indicate more severe symptoms. After calculating of the average scores, those range 1-7.
Measured: 4 weeks after exclusion
GSRS-IBS (the Gastrointestinal Symptom Rating Scale Irritable Bowel Syndrome version) after reintroduction
change of total and subscores before (visit 5) and after (visit 6) REINTRODUCTION of the CLE or COLAP positive food item(s). Total group and responders vs non-responders (as based on the primary outcome). Higher GSRS-IBS indicate more severe symptoms. After calculating of the average scores, those range 1-7.
Measured: 4 weeks after reintroduction
HAD (Hospital Anxiety and Depression scale) after exclusion
change of total and subscores before (visit 4) and after (visit 5) EXCLUSION of the CLE or COLAP positive food item(s). Total group and responders vs non-responders (as based on the primary outcome). Higher HAD scores indicate more symtoms of anxiety and depression. Total score ranging 0-42 and the two subscores (anxiety and depression) ranging 0-21.
Measured: 4 weeks after exclusion
HAD (Hospital Anxiety and Depression scale) after reintroduction
change of total and subscores before (visit 5) and after (visit 6) REINTRODUCTION of the CLE or COLAP positive food item(s). Total group and responders vs non-responders (as based on the primary outcome). Higher HAD scores indicate more symtoms of anxiety and depression. Total score ranging 0-42 and the two subscores (anxiety and depression) ranging 0-21.
Measured: 4 weeks after reintroduction
PHQ12 (the Patient Health Questionnaire - 12) after exclusion
change of scores before (visit 4) and after (visit 5) EXCLUSION of the CLE or COLAP positive food item(s). Total group and responders vs non-responders (as based on the primary outcome). Higher PHQ12 scores indicate more bothersome non-GI somatic symptoms. Scores ranging 0-24, with a subanalysis excluding mentrual problems, leading to a range 0-22.
Measured: 4 weeks after exclusion
PHQ12 (the Patient Health Questionnaire - 12) after reintroduction
change of scores before (visit 5) and after (visit 6) REINTRODUCTION of the CLE or COLAP positive food item(s). Total group and responders vs non-responders (as based on the primary outcome). Higher PHQ12 scores indicate more bothersome non-GI somatic symptoms. Scores ranging 0-24, with a subanalysis excluding mentrual problems, leading to a range 0-22.
Measured: 4 weeks after reintroduction
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 May 2024
- Study start3 Aug 2022
- Primary completion1 Dec 2027 (estimated)
- Study completion1 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Irritable Bowel SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Unblinded elimination and re-introduction of a positive tested food item, identified during CLE or COLAP
- Masking
- None (open label)
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Magnus Simrén
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Magnus Simrén, Sahlgrenska University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06413004
- Sponsor's protocol ID
- 2022-06370-02
- Status last verified
- Jun 2026
- First submitted
- 6 May 2024
- Last updated
- 29 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Brachyspira and Intestinal Allergy-like Immune Reactions in Patients With Irritable Bowel Syndrome (IBS)
- ClinicalTrials.gov ID
- NCT06413004
- Acronym / sponsor ID
- 2022-06370-02
- Conditions
- Irritable Bowel Syndrome, Food Sensitivity
- Keywords
- Irritable Bowel Syndrome, Food Sensitivity, Confocal Laser Endomicroscopy, Colonoscopic Antigen Provocation Test
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Magnus SimrénUniversity, hospital or other
- Study start
- 3 Aug 2022 (actual)
- Primary completion
- 1 Dec 2027 (estimated)
- Study completion
- 1 Dec 2027 (estimated)
- First posted
- 14 May 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to define local immune responses in the GI tract to food antigens in IBS patients, with and without Brachyspira infection, using advanced imaging. We hypothesize that Brachyspira infection can cause IBS symptoms by inducing loss of oral tolerance to dietary antigens through development of food-specific intestinal immune reactions and subsequent development of visceral hypersensitivity.
During this study, the investigators will perform confocal laser endomiscroscopy (CLE) and/or colonoscopic antigen provocation test (COLAP) to test to which food items the participants react to. Furthermore, the investigators will perform rectal barostat examination and a sigmoidoscopy without laxatives. The investigators will collect biological samples and the participants will complete several questionnaires.
Detailed description
The aim of this study is to define local immune responses in the GI tract to food antigens in IBS patients with and without Brachyspira infection using advanced imaging. The investigators hypothesize that Brachyspira infection can cause IBS symptoms by inducing loss of oral tolerance to dietary antigens through development of food-specific intestinal immune reactions and subsequent development of visceral hypersensitivity.
Visit 1: inclusion, questionnaires, blood, rectal barostat examination Visit 2: questionnaires, blood, stool, diaries (food and stool), sigmoidoscopy (without laxantives) Allergologist visit (skin prick test and interpretation blood results) Visit 3A: stool, confocal laser endomicroscopy (CLE) OR colonoscopic antigen provocation test (COLAP) Visit 3B: facultative: in a subset of individuals, both CLE and COLAP will be performed (during separate visits)
Visit 4,5 and 6 only if the CLE or COLAP was positive for (at least) 1 food item
Visit 4: questionnaires and dietician-led instruction which food item to exclude (positive food item(s) during CLE/COLAP,), exclusion for 4 weeks. If both CLE and COLAP are positive, the diet will be COLAP-based.
Visit 5: questionnaires, stool diary, instructions re-introduction food item(s) Visit 6: questionnaires
QUESTIONNAIRES Baseline questionnaires; demographic, symptoms, symptom/medication/diet history, co-morbid medical conditions
IBS symptoms: IBS-Symptom Severity Scale (IBS-SSS) and Gastrointestinal Symptom Rating Scale (GSRS)-IBS
Psychological distress: Hospital Anxiety and Depression Scale (HADS), Patient Health Questionnaire (PHQ)-9 (both visit 1,4,5,6, generalized Anxiety Disorder 7-item scale (GAD-7)
Somatization: PHQ-15 for the number and severity of bodily symptoms.
Gastrointestinal specific anxiety: Visceral Sensitivity Index (VSI).
Sensitivity: Central Sensitization Inventory (CSI).
Food avoidance and restriction: (ARFID).
Stool habits and GI symptoms: 14-day GI symptom diary based on Bristol Stool Form Scale (BSFS).
Quality of life: IBS-Quality of Life (QOL).
Food intake: 4-days food diary, MealQ.
COLONOSCOPIC ALLERGEN PROVOCATION TEST, COLAP:
- A local allergen provocation test, where dietary antigens (soy, wheat, (egg), gluten and milk), with saline and histamine as negative and positive controls, respectively are injected in the rectosigmoid mucosa (similar to skin prick test used for clinical allergy testing).
- The intestinal reaction is determined visually ("wheal and flare reaction"), and biopsies are taken to characterize the immune response.
- Bowel preparation before the investigation follows the normal clinical routine for colonoscopy, and i.v. sedatives and opioids are given during the investigation according to clinical routines at the endoscopy unit
CONFOCAL LASER ENDOMICROSCOPY, CLE, gastroscopy:
- A probe-based endoscopic technique to study intestinal food reactions after iv injection of fluorescein.
- Disruption of the small intestinal barrier in duodenum upon exposure to food antigens (soy, wheat, egg, gluten, milk, and control) can be determined.
VISCERAL SENSITIVITY:
•Rectal barostat sensitivity measurement: With the rectal barostat, the investigators can measure the rectal sensitivity. A balloon is inserted and inflated in the rectum in a controlled setting. The patient indicates when defined sensory thresholds are reached (first feeling of the balloon, urge to empty bowel, discomfort or pain). When the patient indicates discomfort or pain, or another reason to stop, the balloon inflation will be stopped.
SIGMOIDOSCOPY:
•Flexible sigmoidoscopy without bowel preparation, to interfere as little as possible with the normal gut microenvironment; fresh biopsies for specific analyses and biopsies stored for subsequent analyses.
BIOLOGICAL SAMPLES:
- Blood - and plasma samples: Fasting blood samples are taken for routine blood tests (exclusion of organic diseases) and to determine the metabolic profile and genetic and immunological markers of relevance to intestinal function and nerve function. Serum samples will be analyzed with nuclear magnetic resonance (NMR) for metabolomic profile and microbial composition.
- Fecal - and urine sample: The investigators will characterize the composition and function of the metabolome in detail via 16S analysis, metagenomics, transcriptomics, metabolomics, cell culture and cell count. Urine and fecal samples will also be analyzed with nuclear magnetic resonance (NMR) for metabolomic profile and microbial composition.
- Biopsies (location based on the performed endoscopic examination): The investigators will conduct a detailed analysis of immune cells, proteins, nerve cells, and intestinal bacteria which will allow detailed mapping of intestinal function with respect to nerve, immune and barrier function.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Unblinded elimination and re-introduction of a positive tested food item, identified during CLE or COLAP
| Arm | Type | Receives |
|---|---|---|
| Positive food item during CLE or COLAP | Other | Other: Elimination and re-introduction of CLE or COLAP positive food item(s)The food item(s) which were positive during CLE (fluorescein leakage and cell shedding) or COLAP (swelling). |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Patients with IBS diagnosis according to their treating physician (ROME IV).
- Association between intake of food and GI symptoms.
- Witnessed written informed consent prior to any study procedures.
- Patients who are capable to understand the study and the questionnaires, and to comply with the study requirements.
Key exclusion criteria (7 listed)
- Patients with relevant concurrent organic GI disease (inflammatory bowel disease, abdominal cancer), or a major disease such as diabetes, uncontrolled thyroid disease, heart disease, kidney disease, liver disease, and active malignant disease (not those that were in remission at least 5 years).
- Patients with a history of bowel surgery (not appendectomy or cholecystectomy) that affects GI motility.
- Patients with systemic food allergy as evidenced by positive allergy tests (blood, prick test).
- Clinical history of severe allergic reactions.
- Patients with concurrent major confounding condition(s) based on the clinician's judgement, e.g. DOMINANT psychiatric disorder, vital depression, alcohol or substance abuse in the last 2 year.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Elimination and re-introduction of CLE or COLAP positive food item(s)Elimination (4 weeks) and re-introduction (4 weeks) of all CLE or COLAP positive food item(s) | Other | Positive food item during CLE or COLAP |
Primary outcome
IBS-SSS (Irritable Bowel Syndrom Severity Scoring System) after exclusion (proportion).
Time frame: 4 weeks after exclusion
the proportion of participants with an IBS-SSS reduction of ≥50 points, measured before (visit 4) and after (visit 5) exclusion of the CLE or COLAP positive food item(s) (= responders). IBS-SSS: higher IBS-SSS indicate more severe symptoms. Scores ranging 0-500.
9 secondary outcomes
IBS-SSS (Irritable Bowel Syndrom Severity Scoring System) after exclusion (absolute)
Time frame: 4 weeks after exclusion
IBS-SSS (Irritable Bowel Syndrom Severity Scoring System) after reintroduction (proportion)
Time frame: 4 weeks after reintroduction
IBS-SSS (Irritable Bowel Syndrom Severity Scoring System) after reintroduction (absolute)
Time frame: 4 weeks after reintroduction
GSRS-IBS (the Gastrointestinal Symptom Rating Scale Irritable Bowel Syndrome version) after exclusion
Time frame: 4 weeks after exclusion
GSRS-IBS (the Gastrointestinal Symptom Rating Scale Irritable Bowel Syndrome version) after reintroduction
Time frame: 4 weeks after reintroduction
HAD (Hospital Anxiety and Depression scale) after exclusion
Time frame: 4 weeks after exclusion
HAD (Hospital Anxiety and Depression scale) after reintroduction
Time frame: 4 weeks after reintroduction
PHQ12 (the Patient Health Questionnaire - 12) after exclusion
Time frame: 4 weeks after exclusion
PHQ12 (the Patient Health Questionnaire - 12) after reintroduction
Time frame: 4 weeks after reintroduction
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jun 2026.
Related trials for Irritable Bowel Syndrome
RecruitingObservational study
Abdominal Symptoms and Rosacea: An Observational Study on the Association Between Irritable Bowel Syndrome (IBS) and the Gut-Skin Axis
IBS (Irritable Bowel Syndrome), Rosacea
Recruiting
Stress Reduction and Lifestyle Modification in Irritable Bowel Syndrome Patients
Irritable Bowel Syndrome
Recruiting
Exercise Interventions and Dietary Advice in Fibromyalgia and IBS
Fibromyalgia, Irritable Bowel Syndrome
RecruitingPhase 2
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)
Irritable Bowel Syndrome, Constipation
RecruitingPhase 2
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
Irritable Bowel Syndrome, Diarrhea
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Elimination and re-introduction of CLE or COLAP positive food item(s) in people with Irritable Bowel Syndrome and Food Sensitivity, run by Magnus Simrén at 1 site in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 29 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Magnus Simrén, MD PhD (0046313428107, magnus.simren@medicine.gu.se), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
IBS-SSS (Irritable Bowel Syndrom Severity Scoring System) after exclusion (proportion). (time frame: 4 weeks after exclusion). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jun 2026.